Improving Diabetes Care at Primary Health Centers in Nigeria
Tests a diabetes care program, including metformin and glimepiride, in adults at Nigerian health centers.
Plain-language title generated from the registry record
Registry title: Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3
Key facts
- Where
- Abaji, Abuja, Bwari, Gwagwalada, Kuje, and Kwali, NigeriaSee the 10 sites
Where in Nigeria
- New Township AbajiAbaji, NigeriaTaking people
- Gbagarape PHCAbuja, NigeriaTaking people
- Gidan MangoroAbuja, NigeriaTaking people
- Pyakasa PHCAbuja, NigeriaTaking people
- ByazhinBwari, NigeriaTaking people
- Gtc GwagwaladaGwagwalada, NigeriaTaking people
- Old KutunkuGwagwalada, NigeriaTaking people
- Kuje PHCKuje, NigeriaTaking people
- Dabi BakoKwali, NigeriaTaking people
- KAWLIKwali, NigeriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Washington University School of Medicine
- Trial code
- NCT07589387
- Record updated
- 16 October 2026
- Original description
The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary healthcare centers (PHCs) in the Federal Capital Territory (FCT). This program demonstrated significant improvements in hypertension treatment and control. The focus of aim 3 will be evaluating diabetes management through the implementation of the HEARTS-D bundle in 10 PHCs across the FCT that previously participated in the initial HTN Program.Read full original descriptionShow less
Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design - Aim 3
The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary healthcare centers (PHCs) in the Federal Capital Territory (FCT). This program demonstrated significant improvements in hypertension treatment and control. The focus of aim 3 will be evaluating diabetes management through the implementation of the HEARTS-D bundle in 10 PHCs across the FCT that previously participated in the initial HTN Program.
Inclusion: Aim 3 Inclusion Criteria:; Patients will be screened for diabetes with symptoms of hyperglycemia or BMI >25 kg/m2 and over the age of 18 years old. Upon first or previous diagnosis, diabetes patients will be registered; Adults (≥18 years),; Patients with previous diabetes diagnosis; Patients with persistently elevated random glucose >200 mg/dl, fasting glucose >126 mg/dl, or hemoglobin A1c >6.5% on two or more occasions (when available); Patients taking glucose lowering medications; Pregnant women are eligible for this program, or; Cognitively impaired adults are eligible for this program.
Exclusion: - This program will not include any of the following special populations:; Individuals who are not yet adults (minors): i.e. infants, children, or teenagers <18 years old, or; Prisoners or other detained individuals.